Genentech Inc. has accused Samsung Bioepis Co. in Delaware federal court of infringing 21 patents for its breast cancer drug Herceptin.
September 05, 2018 at 05:32 PM
1 minute read
Genentech Inc. has accused Samsung Bioepis Co. in Delaware federal court of infringing 21 patents for its breast cancer drug Herceptin.
In the lawsuit, filed Tuesday in the U.S. District Court for the District of Delaware, Genentech aims to stave off the latest threat of biosimilar competition for the drug, which is used to treat about 20 percent of the 2.8 million women who suffer from a form of breast cancer known as HER2-positive.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
